Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes.

Irini P ChatziralliShane O ReganRyian MohamedJames TalksSobha Sivaprasadnull null

Published in: Eye (London, England) (2018)

Very old patients with nAMD benefited from aflibercept, but not to the same degree as the younger patients. The study showed that, on an average, the very elderly patients were able to adhere to the intensive anti-VEGF treatment regimens.

Keyphrases

age related macular degeneration
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
vascular endothelial growth factor
metabolic syndrome
skeletal muscle